Difference between revisions of "Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative"

From blackwiki
Jump to navigation Jump to search
(Remove now unnecessary 1px width hack from table footer cell)
imported>Medgirl131
 
(11 intermediate revisions by 4 users not shown)
Line 1: Line 1:
{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}"
+
#REDIRECT [[Template:Results of the Women's Health Initiative menopausal hormone therapy randomized controlled trials]]
|+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative
 
|-
 
! rowspan="2" | Event !! rowspan="2" style="width: 205px;" | Relative Risk {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} vs. placebo at 5.2 years (95% {{abbr|CI|confidence interval}}{{NoteTag|Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.}}) !! style="width: 75px;" data-sort-type="number" | Placebo<br />(n = 8102) !! style="width: 75px;" data-sort-type="number" | {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}}<br />(n = 8506)
 
|-
 
! colspan="2" | Absolute Risk per 10,000 Women-Years
 
|-
 
| [[Coronary heart disease]] events<br />({{dfn|non-fatal [[myocardial infarction]]}}, {{dfn|death|Coronary heart disease death|}}) || 1.29 (1.02–1.63)<br />1.32 (1.02–1.72)<br />1.18 (0.70–1.97) || 30<br />23<br />6 || 37<br />30<br />7
 
|-
 
| [[Invasive breast cancer]]{{efn|Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.}} || 1.26 (1.00–1.59) || 30 || 38
 
|-
 
| [[Stroke]] || 1.41 (1.07–1.85) || 21 || 29
 
|-
 
| [[Pulmonary embolism]] || 2.13 (1.39–3.25) || 8 || 16
 
|-
 
| [[Colorectal cancer]] || 0.63 (0.43–0.92) || 16 || 10
 
|-
 
| [[Endometrial cancer]] || 0.83 (0.47–1.47) || 6 || 5
 
|-
 
| [[Hip fracture]] || 0.66 (0.45–0.98) || 15 || 10
 
|-
 
| Death due to causes other than above || 0.92 (0.74–1.14) || 40 || 37
 
|-
 
| Global Index{{efn|A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.}} || 1.15 (1.03–1.28) || 151 || 170
 
|-
 
| [[Deep vein thrombosis]]{{efn|name=not-gi|Not included in Global Index.}} || 2.07 (1.49–2.87) || 13 || 26
 
|-
 
| [[Vertebral fracture]]s{{efn|name=not-gi}} || 0.66 (0.44–0.98) || 15 || 9
 
|-
 
| Other [[osteoporotic fracture]]s{{efn|name=not-gi}} || 0.77 (0.69–0.86) || 170 || 131
 
|-
 
! colspan="10" | Sources: <ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref>
 
|}<!--
 
 
 
--><noinclude>{{Documentation|content=
 
{{Improve documentation|date=March 2019}}
 
==Notes and references==
 
{{Reflist}}
 
{{Notelist}}
 
{{Notefoot}}
 
}}
 
[[Category:Medication templates]]
 
[[Category:Templates that generate named references]]
 
</noinclude>
 

Latest revision as of 10:15, 4 March 2020